NCT07289100Recruiting
Novel Sensors and Artificial Intelligence for Detection of Acute Pulmonary Exacerbations in Cystic Fibrosis and Bronchiectasis
Novel Sensors and Artificial Intelligence for Detection of Acute Pulmonary Exacerbations in Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis
Source: ClinicalTrials.gov · Last updated 17 Dec 2025
Brief summary (registry, in English)
The goal of this observational study is to learn about new sensors that measure changes in the body that happen during a chest infection, such as breathing rate and heart rate. This study will be with adults who have either cystic fibrosis or bronchiectasis who start treatment with intravenous antibiotics (usually for around 2 weeks). The main question it aims to answer is the change in sensor measure (such as heart rate) between the start and end of treatment for a chest infection. No follow up visits are required for this study.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 17 Nov 2025
- Start date
- 30 Sept 2025
- Primary completion date
- 31 Mar 2026
- Lead sponsor
- Papworth Hospital NHS Foundation Trust
- Diseases
- Cystic fibrosis
- NCT number
- NCT07289100
What you commit to
- Study type: Observational
- Planned participants: 50
- From 30 Sept 2025 to the primary completion date, 31 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Lung transplant recipients or on lung transplant waiting list
Other illness
- Use of long-term oxygen therapy (LTOT) or non-invasive ventilation to manage respiratory failure
Other
- Patients unable to provide written informed consent
- Patients unwilling to consent to their link anonymised data from home monitoring being used for research
- Considered unsuitable for home monitoring in the opinion of the investigator
- Patients being admitted for elective antibiotic treatment (i.e. not being admitted for acute APE treatment)
Who the study is looking for
- ≥ 18 years old
- Diagnosis of CF based on genetic testing and /or sweat chloride levels or CT confirmed diagnosis of non-CF bronchiectasis
- Under the care of Royal Papworth Hospital
- Starting IV antibiotics for treatment of APE as defined by the Hill Criteria ²
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Royal Papworth Hospital NHS Foundation Trust Coordinator of this site? Confirm its status | Cambridge | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.